How device decision timing works

Unlike drugs, devices have no public “PDUFA date”. FDA does not announce when a device decision is due. Companies sometimes give a rough expectation, and the only fixed public markers are advisory panel meetings, which are posted in the Federal Register.

The best baseline is FDA’s MDUFA V performance goals for fiscal years 2026 and 2027:

PathwayFDA-day goalTotal time to decision goal
510(k)Decision within 90 FDA days for 95%112 days (108 if earlier goals met)
De NovoDecision within 150 FDA days for 70% (80% or 90% if earlier goals met)Not set as a single figure
Original PMA (no panel)Decision within 180 FDA days for 90%285 days (275 or 270 if earlier goals met)

“FDA days” exclude time the clock is stopped while the sponsor answers questions, so calendar time is longer. Panel-track PMAs, which go to an advisory committee, usually take longer still.

MDUFA V expires on 30 September 2027. A draft MDUFA VI commitment letter was published in July 2026 and is due to Congress by 15 January 2027, so goals may change for submissions from fiscal year 2028.

A mid-year analysis by BTIG analyst Ryan Zimmerman, reported by MedTech Dive and MD+DI, found that FDA is authorizing more devices in 2026 but taking longer to do it. Figures are for January to June 2026.

PathwayFirst half 2026Full-year projectionAverage time to decision
Original PMA23 approvals (up 10 year on year)about 51about 599 days, versus about 402 in 2025; about 339 excluding three outliers
510(k)1,669 clearancesabout 3,239about 156 days, up about 5%
De Novo14 grants27about 341 days, up about 8%
Panel-track supplements16 approvals35about 307 days, up 6.5%

For background, FDA cut more than 3,000 roles in 2025 and is now hiring more than 2,000, according to MedTech Dive.

Other trends shaping 2027 forecasts:

  • AI and software guidance. CDRH’s proposed FY2027 guidance list includes a final guidance on AI-enabled device software functions and a draft on generative AI conversational devices for mental disorders. Comments are open to 30 November 2026.
  • Breakthrough Device payments. Devices designated by 30 September 2026 keep alternative Medicare payment eligibility (NTAP and TPT) for FY2028 and FY2029. That route is now closed to newly designated devices.
  • Higher fees. For FY2027, the PMA application fee is $636,732.

Device decisions to watch

DeviceCompanyPathwayStatusExpected timing
Galleri multi-cancer early detection blood test (adults 50+)GRAILPMAAdvisory panel voted on 23 Sep 2026: safety unanimous, effectiveness 6 to 4, benefit-risk 7 to 2 with 1 abstentionCompany expects FDA’s decision “in the coming months”
Acclaim fully implanted cochlear implantEnvoy MedicalModular PMA, Breakthrough DeviceTwo of four modules submitted (30 Jun and 12 Oct 2026)Final modules toward the end of Q2 2027; decision after that

For Galleri, the split effectiveness vote means a label narrower than requested, or conditions such as post-approval studies, are possible. FDA is not bound by the panel.

Other public markers on the calendar:

  • 19 November 2026: the Microbiology Devices Panel will discuss pathogen-agnostic sequencing for emergency preparedness. This is a general topic, not a single product.
  • By 15 January 2027: the MDUFA VI package is due to Congress.
  • 30 September 2027: MDUFA V expires.

For 510(k) and De Novo submissions, a practical forecast is the 2026 average decision time: about 156 days for a 510(k) and about 341 days for a De Novo, counted from submission. Adjust for any requests for additional information.

Using device forecasts in AI and RAG

  1. Index sources by type. Keep MDUFA goals, FDA databases, Federal Register panel notices, and company disclosures as separate sources.
  2. Record the submission date and pathway for each device you track, and compute expected windows from current average review times.
  3. Store panel votes and briefing documents with the device record.
  4. Attach the outcome. After a decision, link the FDA database entry (PMA, 510(k), or De Novo).
  5. Re-check the goals when MDUFA VI is enacted.

Common mistakes

  • Treating MDUFA FDA-day goals as calendar days.
  • Assuming a positive panel vote means approval.
  • Forecasting from 2025 review times, which were shorter.
  • Relying on a single analyst average affected by outliers.

Checklist

  • Pathway and submission date recorded
  • Forecast window based on 2026 times
  • Panel notices and votes linked
  • Outcome linked to the FDA database entry
  • MDUFA VI changes tracked

How AskDona helps

AskDona checks your submission tracker and investor guidance against the FDA records, panel documents, and company disclosures you load. It flags any forecast date without a source.

Run a sample device approval forecast check

AskDona shows the evidence; your regulatory and investor relations teams decide.

Editor’s note. This article is general information, not investment, legal, or regulatory advice. Review-time figures come from a third-party analysis of FDA data through June 2026. Device decision timing is not published by FDA and can change at any time.

FAQ

Does FDA publish dates for device decisions? No. Only advisory panel meetings are announced in advance.

How long does a PMA take in 2026? On average, about 599 days in the first half of 2026, or about 339 days excluding three outliers, according to a BTIG analysis.

How long does a 510(k) take? About 156 days on average in the first half of 2026. The MDUFA V goal is a decision within 90 FDA days for 95% of submissions.

When will FDA decide on Galleri? GRAIL expects a decision in the coming months after the September 2026 panel vote.

References

All pages opened and checked by October 29, 2026.

SourceWhat it supports
FDA: MDUFA V commitment letter (PDF)Review goals, FY2026 to 2027
MedTech Dive: More devices, taking longer (Jul 2026)BTIG figures, staffing
MD+DI: FDA approval timelines in 2026Projections and averages
Avania: MedTech Industry Pulse, July 2026MDUFA VI timeline, FY2027 fees, Breakthrough payments
MedTech Dive: MDUFA VI agreement (Apr 2026)MDUFA VI scope
FDA Law Blog: CDRH FY2027 guidancesAI and software guidance list
Federal Register: Galleri panel noticePMA, intended use
GRAIL: Panel votes in favorVote results, expected timing
Envoy Medical: Second PMA moduleModule timing
Federal Register: Microbiology panel notice19 Nov 2026 meeting